Search

for
Search:

Research

5 / 1000+ results

research Use of genetics in the prediction of success in male pattern hair loss therapy and mechanistic studies

February 2026 in “Frontiers in Pharmacology”

This review suggests a shift toward genetically informed treatments for male pattern hair loss by integrating genetic insights and pharmacogenetic markers into therapeutic decision-making.

research From gene to therapy in spinal and bulbar muscular atrophy: Are we there yet?

17 citations , July 2017 in “Molecular and Cellular Endocrinology”

The authors reviewed the mechanisms behind Kennedy's disease, noting advances in therapeutic strategies such as androgen deprivation and gene silencing that may soon expand treatment options for this incurable neuromuscular condition.

Double Knockdown of the Androgen Receptor Target Genes DKK1 and SFRP1 Does Not Potentiate the Hair Growth-Promoting Effect of SFRP1 Silencing in Healthy Human Hair Follicles Ex Vivo

research Double Knockdown of the Androgen Receptor Target Genes DKK1 and SFRP1 Does Not Potentiate the Hair Growth-Promoting Effect of SFRP1 Silencing in Healthy Human Hair Follicles Ex Vivo

February 2026 in “International Journal of Molecular Sciences”

This study found that knocking down the gene SFRP1 in human hair follicles ex vivo prolonged the hair growth phase and increased keratinocyte proliferation, suggesting potential as a therapeutic target for maintaining hair growth in male pattern baldness, while DKK1 knockdown showed no effect.

research TMPRSS2: A Key Host Factor in SARS-CoV-2 Infection and Potential Therapeutic Target

4 citations , June 2025 in “Medeniyet Medical Journal”

This review explores the role of the TMPRSS2 gene in facilitating SARS-CoV-2 infection and its potential as a therapeutic target in COVID-19 and other respiratory infections, highlighting challenges in developing selective inhibitors.

research Prostaglandin D2-Mediated DP2 and AKT Signal Regulate the Activation of Androgen Receptors in Human Dermal Papilla Cells

18 citations , February 2018 in “International Journal of Molecular Sciences”

This study found that prostaglandin D2 promotes androgen receptor and AKT signaling in human dermal papilla cells through the DP2 receptor, potentially contributing to androgenetic alopecia.

View more "rna-based androgen receptor silencing" in research →

Community Join

5 / 26 results

community What new hair-loss treatments actually look exciting right now (Oct 2025)

171 upvotes 11 months ago

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

community We already know how to permanently fix hair loss. The science is done. The only thing missing is the funding to run one experiment.

in Technology 613 upvotes 4 months ago

A permanent hair loss solution could involve reprogramming hair follicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.

community Has anyone powered through the creatine shedding (via increased androgen receptor sensitivity) and stabilized?

9 upvotes 1 year ago

Creatine may cause increased hair shedding due to androgen receptor sensitivity, despite limited evidence. The user is using dutasteride and minoxidil and seeks advice on whether shedding will stabilize, with suggestions including GHK-Cu and RU58841.

community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

133 upvotes 2 years ago

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

community End of Hair loss ( AGA ) ? Since they produce it in china probably we don’t need to wait other 10 yrs😁

276 upvotes 6 months ago

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

View more "rna-based androgen receptor silencing" in community →